Morgan Stanley’s BioAtla BCAB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $8.92K | Buy |
1,109
+236
| +27% | +$2.76K | ﹤0.01% | 6981 |
|
|
2025
Q4 | $24.8K | Buy |
873
+564
| +183% | +$22.1K | ﹤0.01% | 6624 |
|
|
2025
Q3 | $10.6K | Sell |
309
-6,002
| -95% | -$139K | ﹤0.01% | 6882 |
|
|
2025
Q2 | $125K | Sell |
6,311
-5,601
| -47% | -$114K | ﹤0.01% | 6049 |
|
|
2025
Q1 | $207K | Sell |
11,912
-10,177
| -46% | -$218K | ﹤0.01% | 5717 |
|
|
2024
Q4 | $653K | Sell |
22,089
-15,075
| -41% | -$1.27M | ﹤0.01% | 5310 |
|
|
2024
Q3 | $3.27M | Buy |
37,164
+69
| +0.2% | +$5.79K | ﹤0.01% | 4297 |
|
|
2024
Q2 | $2.54M | Sell |
37,095
-1,108
| -3% | -$132K | ﹤0.01% | 4399 |
|
|
2024
Q1 | $6.57M | Sell |
38,203
-38,322
| -50% | -$4.76M | ﹤0.01% | 3690 |
|
|
2023
Q4 | $9.41M | Buy |
76,525
+44,509
| +139% | +$3.86M | ﹤0.01% | 3964 |
|
|
2023
Q3 | $2.72M | Sell |
32,016
-1,822
| -5% | -$232K | ﹤0.01% | 4187 |
|
|
2023
Q2 | $5.08M | Sell |
33,838
-3,732
| -10% | -$642K | ﹤0.01% | 3769 |
|
|
2023
Q1 | $5.03M | Buy |
37,570
+1,143
| +3% | +$206K | ﹤0.01% | 3787 |
|
|
2022
Q4 | $15M | Buy |
36,427
+3,472
| +11% | +$1.44M | ﹤0.01% | 2633 |
|
|
2022
Q3 | $12.7M | Buy |
32,955
+11,379
| +53% | +$3.72M | ﹤0.01% | 2700 |
|
|
2022
Q2 | $3.08M | Sell |
21,576
-10,304
| -32% | -$1.64M | ﹤0.01% | 4179 |
|
|
2022
Q1 | $7.97M | Buy |
31,880
+18,675
| +141% | +$7.81M | ﹤0.01% | 3175 |
|
|
2021
Q4 | $13M | Buy |
13,205
+8,529
| +182% | +$10.9M | ﹤0.01% | 2635 |
|
|
2021
Q3 | $6.88M | Buy |
4,676
+4,397
| +1,576% | +$8.57M | ﹤0.01% | 3342 |
|
|
2021
Q2 | $591K | Buy |
+279
| New | +$630K | ﹤0.01% | 5418 |
|
|
2021
Q1 | – | Sell |
-4
| Closed | -$7K | – | 7485 |
|
|
2020
Q4 | $7K | Buy |
+4
| New | +$6.69K | ﹤0.01% | 6710 |
|
Other funds holding BCAB
ACA
VCM
